ATENOLOL
Cerebrovascular Accidents
Northern California Institute of Research and EducationSmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
132 Active assets in the Cerebrovascular Accidents cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aggrenox Boehringer Ingelheim | Phase 4 | BBB |
INCOBOTULINUMTOXINA Parc de Salut Mar | Phase 4 | BBB |
Dextromethorphan University of Florida | Phase 4 | BBB |
Nerinetide NoNO Inc. | Phase 3 | BBB |
Rivaroxaban China National Center for Cardiovascular Diseases | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
ATENOLOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →